This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Organic cosolvent may be needed for hydrophobic sequences |
| pH adjustment | Sequence-dependent | Test small volumes before preparing the full solution |
| Filtration | 0.22 µm sterile filter | Can remove particles but may bind or remove aggregates |
| Aliquot size | Single-use volume | Reduces repeated freeze-thaw cycles |
| Post-reconstitution storage | -20 °C to -80 °C | Follow supplier or protocol; avoid frost-free cycles |
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
CGRP mediates its effects through a heteromeric receptor composed of a G protein-coupled receptor called calcitonin receptor-like receptor (CALCRL) and RAMP1. CGRP receptors are found throughout all the body, suggesting that the protein may modulate a variety of physiological functions in all major systems (e.g., respiratory, endocrine, gastrointestinal, immune, and cardiovascular). These transmembrane receptors form folded accordion-like structures embedded in the cell membrane with loops of protein on the inside (intracellular loops) and outside (extracellular loops) of the membrane. The second extracellular loop is fundamental for ligand-induced activation, with key interactions of R274/Y278/D280/W283.
Another possibility is that the central opioid system may have low endogenous functionality in most individuals, becoming active only in the presence of exogenously administered opioid receptor agonists or with stimulation by endogenous opioids induced by pain or stress. A third possibility is that normal individuals may experience different side effects with naltrexone than people with addictive disease such as alcohol or opioid dependence, who may have altered opioid tone or responsiveness. It is notable in this regard that most studies of naltrexone have been in people with substance dependence. Naltrexone may also initially produce opioid withdrawal-like symptoms in a small subset of people not dependent on opioids:
It also raised tariffs on imports of Chinese steel, aluminum, and medical materials. In April 2024, Biden signed the Protecting Americans from Foreign Adversary Controlled Applications Act, which would ban social networking services if they are determined by the president and relevant provisions to be a "foreign adversary controlled application". The act explicitly applies to ByteDance Ltd. and its subsidiaries, which are based in China. It ceases to be applicable if the application is divested and no longer considered to be controlled by a foreign adversary of the United States. Biden had signed the No TikTok on Government Devices Act in December 2022, prohibiting the use of TikTok on devices owned by the federal government.
Sources: en.wikipedia.org
== Documentation == The documentation of activities by pharmaceutical manufacturers is a license-to-operate endeavor, supporting both the quality of the product produced and satisfaction of regulators who oversee manufacturing operations and determine whether a manufacturing process may continue or must be terminated and remediated.
== Conferences == The society's annual meeting is held in the first week of September as well as regular special interest group meetings (Lipidomics, MALDI & Imaging, Ambient Ionisation, Environmental & Food Analysis) through the year, in locations throughout the United Kingdom. Locations of the society's annual meetings beginning in 1965:
=== Pharmacodynamics === Dihydroergotamine's antimigraine activity is due to its action as an agonist at the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors. It also interacts with other serotonin, adrenergic, and dopamine receptors. Dihydroergotamine is an agonist of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy. In spite of acting as an agonist of the serotonin 5-HT2A receptor, dihydroergotamine has been described as non-hallucinogenic. This is also the case with certain other ergoline derivatives, such as bromocriptine and pergolide.
27 March – Humza Yousaf is elected as the Leader of the Scottish National Party and subsequently, First Minister of Scotland. He is the youngest holder of the position in history at just 37 years of age upon entry to office, the first from an ethnic minority background, the first Muslim to hold the office and the first First Minister with facial hair. 28 March Humza Yousaf is confirmed as Scotland's First Minister by a vote in the Scottish Parliament. Kate Forbes is to leave the Scottish Government after turning down a position in the Yousaf ministry. 29 March – Humza Yousaf is sworn in as Scotland's First Minister at Edinburgh's Court of Session and begins naming his Cabinet. 30 March The Parliamentary Standards Committee recommends that former Scottish National Party MP Margaret Ferrier be suspended from the House of Commons for 30 days for breaching COVID-19 regulations in September 2020 when she took a train home from London following a positive COVID test. Humza Yousaf attends his first session of First Minister's Questions since his election as First Minister. The session is interrupted on several occasions by climate change protestors, forcing the Presiding Officer of the Scottish Parliament to clear the gallery of visitors.
Sources: en.wikipedia.org
=== Trypsin === Trypsin (EC 3.4.21.4) is a serine protease that cleaves protein substrates after lysine or arginine residues using a catalytic triad to perform covalent catalysis, and an oxyanion hole to stabilise charge-buildup on the transition states.
Other effects have been reported to include confusion, lethargy, laziness, sleepiness, lightheadedness, feeling faintish and actual fainting, brief but repeated periods of amnesia, fear of psychosis, pupil dilation, paresthesia, nausea, vomiting, abdominal cramps, diarrhea, and muscle tremors, among others. The drug was described as a "seminal" or "archetypal" psychedelic in PiHKAL.
Estradiol dienanthate (EDE), sold under the brand names Climacteron among others, is a long-acting estrogen medication which was previously used in menopausal hormone therapy for women and to suppress lactation in women. It was formulated in combination with estradiol benzoate (EB), a short-acting estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), a long-acting androgen/anabolic steroid. EDE has not been made available for medical use alone. The medication, in combination with EB and TEBH, was given by injection into muscle once or at regular intervals, for instance once every 6 weeks. Side effects of EDE include breast tenderness, breast enlargement, nausea, headache, and fluid retention. EDE is an estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen. EDE was first described by 1959. It was previously available in Canada and Germany but was discontinued by 2005. The medication is no longer available in any form.
== Health effects == Overall, diets high in red and processed meats are associated with an increased risk of type 2 diabetes (T2D), cardiovascular disease (CVD), cancer (particularly colorectal cancer), and all-cause mortality. The body of epidemiological data showing their associations with T2D, CVD, and cancer is large and consistent. The associations are strongest for processed meat, which is meat that has undergone salting, curing, fermentation, smoking, or other processes to enhance flavor or improve preservation, such as bacon, ham, salami, pepperoni, hot dogs, and some sausages. A 2025 umbrella review found that a high intake of red meat is associated with an increased all-cause mortality risk. There are no long-term randomized controlled trials that have investigated red meat consumption and disease outcomes, and such trials are unlikely to be conducted due to ethical, financial and practical reasons. Most of the data on red meat and health effects is from long-term epidemiological studies.
2024 – David Perlman Memorial Award, American Chemical Society, Biochemical Technology. 2024 – Founder Award, Kendall Square Association. 2024 – American Association for Cancer Research Academy, Fellow. 2023 – Australian Academy of Technological Science & Engineering, Fellow. 2021 – Outstanding Scientist Award, AAISCR Cancer Research Annual Meeting. 2019 – Honorary Degree, DSc (Medicine) University of London – Institute Cancer Research. 2017 – Catalyst Award, Science Club for Girls. 2017 – Innovation at the Intersection Award, Xconomy Awards, Biotech Week Boston. 2017 – Honorary Degree, Doctorate Utrecht University, the Netherlands. 2017 – AIMBE STEM Award, American Institute for Medical and Biological Engineering. 2015 – 20th Heinz Award for Technology, Heinz Family Foundation. 2015 – American Academy of Arts and Sciences, Fellow. 2014 – Lemelson-MIT Prize, Lemelson-MIT Program. 2014 – Pioneers of Miniaturization Prize, Lab on a Chip Lectureship at MicroTAS. 2011 – Massachusetts Academy of Sciences, Fellow. 2011 – Biomedical Engineering Society, Fellow. 2011 – Brown Engineering Alumni Medal, Brown University School of Engineering. 2011 – Thomas A. McMahon Mentoring Award, MIT, Health Sciences & Technology. 2010 – John J. and Dorothy Wilson Professor, MIT, HST & EECS, Endowed Chair. 2010 – Young Investigator Award, American College of Clinical Pharmacology. 2009 – American Society for Clinical Investigation, Fellow. 2005 – American Institute for Medical and Biological Engineering, Fellow. 2003 – Y.C. Fung Young Investigator Award, American Society of Mechanical Engineers.
Sources: en.wikipedia.org
It should first equilibrate to room temperature in a sealed container to prevent condensation on the cold contents. Opening too soon can introduce moisture and reduce stability, and the waiting period depends on vial size and packaging.
Hydrophobic peptides may require buffers, organic cosolvents, or a stepwise solvent approach. Small amounts of acetonitrile, methanol, or dimethyl sulfoxide are sometimes used, followed by dilution into aqueous buffer. The exact solvent system should be tested for the specific sequence.
Single-use aliquots limit freeze-thaw cycling, which can cause aggregation, precipitation, or loss of activity. They also reduce repeated opening of the same container and lower contamination risk. Labeling each aliquot supports traceability and consistent use.
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.